| Laurent Fischer |
Dr. Laurent Fischer, MD, is a President, Chief Executive Officer & Director at Adverum Biotechnologies, Inc., an Independent Director at Mirum Pharmaceuticals, Inc., a Chairman at CTI BioPharma Corp. and an Independent Director at Lycia Therapeutics, Inc. He is on the Board of Directors at Adverum Biotechnologies, Inc., Mirum Pharmaceuticals, Inc., Lycia Therapeutics, Inc. and dpa Deutsche Presse-Agentur GmbH.
Dr. Fischer was previously employed as an Independent Director by Senti Sub I, Inc., a Senior Advisor by Frazier Management LLC, a Senior Vice President by Allergan Ltd. (Ireland), a Chief Executive Officer by Tobira Therapeutics, Inc., a Chairman, President & Chief Executive Officer by Jennerex Biotherapeutics, Inc., a Chairman & Chief Executive Officer by Tobira Therapeutics, Inc. /Old/, a Vice Chairman by Ocera Therapeutics, Inc. /Old/, a Vice President-Corporate Development by MedVantx, Inc., a President & Chief Executive Officer by Auxeris Therapeutics, Inc., a President & Chief Operating Officer by Rxcentric, Inc., a Senior Vice President-Global Virology by DuPont Merck Pharmaceutical Co., a Senior Vice President-Global Virology by DuPont Pharmaceuticals Co., and a Medical Director-Virology Group by Hoffmann-La Roche, Inc. He also served on the board at Panacos Pharmaceuticals, Inc. and AIDS Healthcare Foundation.
He received his undergraduate degree from the University of Geneva and a doctorate degree from the University of Geneva. |
| Kalliopi Stasi |
Kalliopi Stasi is currently working as the Senior Vice President-Clinical Development at Adverum Biotechnologies, Inc. Prior to this, she worked as the Vice President-Clinical Development at Tenpoint Therapeutics Ltd. in 2022. Ms. Stasi holds a doctorate degree from the University of Patras. |
| Peter Soparkar |
Peter Soparkar is currently the Chief Operating & Legal Officer at Adverum Biotechnologies, Inc. Prior to this, he worked as the Secretary, Chief Legal Officer & Head-Compliance at Myriad Women's Health, Inc. from 2016 to 2018. Before that, he served as the Vice President & Associate General Counsel at Jazz Pharmaceuticals Plc from 2006 to 2016. Mr. Soparkar completed his undergraduate degree at Oberlin College and his graduate degree at New York University School of Law. |
| R. Andrew Ramelmeier |
R. Andrew Ramelmeier is currently the Chief Technology Officer at Adverum Biotechnologies, Inc. He previously held positions as the Executive Director-Pharmaceutical Development at Centocor, Inc. from 2001 to 2005, Vice President-Process Sciences at Johnson & Johnson, VP-Manufacturing, Process Sciences & Facilities at BioMarin Pharmaceutical, Inc. from 2006 to 2014, Senior Vice President-Technical Operations at Portola Pharmaceuticals LLC from 2014 to 2017, and Chief Manufacturing & Quality Officer, Senior VP at Sangamo Therapeutics, Inc. from 2018 to 2023. He obtained his undergraduate degree from The Johns Hopkins University in 1984 and his doctorate degree from the University of California, Berkeley in 1989. |
| Heikki Jouttijärvi |
Heikki Jouttijärvi currently works at Adverum Biotechnologies, Inc., as Senior VP-Manufacturing & Supply Chain Management from 2023. Mr. Jouttijärvi also formerly worked at Menlo Therapeutics, Inc., as Vice President-Technical Operations and Santen Pharmaceutical Co., Ltd., as VP, Head-Global External Manufacturing & Sourcing from 1999 to 2015. Mr. Jouttijärvi received his graduate degree from the University of Helsinki. |
| Bill Tan |
Bill Tan is currently the SVP & Head-Global Clinical Operations at Adverum Biotechnologies, Inc. He previously worked as the Director-Clinical Development at Allergan, Inc. from 2018 to 2020, the Director-Medical Affairs at Anacor, Inc. in 2015 and 2016, and the Director-Medical Information at Onyx Pharmaceuticals, Inc. in 2014 and 2015. Dr. Tan obtained his undergraduate degree from the University of California, Los Angeles and his doctorate degree from the University of California, San Francisco. |
| Star Seyedkazemi |
Star Seyedkazemi is currently the Chief Development Officer at Adverum Biotechnologies, Inc. Prior to this, Star held the position of Senior Director-Clinical Research at Tobira Therapeutics, Inc. from 2015 to 2016. Star then worked at Allergan, Inc. as an Associate Vice President-Clinical Development from 2018 to 2020. Star also served as an Associate Vice President at AbbVie, Inc. Star's most recent former position was as Vice President-Portfolio Management at Pliant Therapeutics, Inc. from 2020 to 2021. Star obtained an undergraduate degree from Florida Atlantic University and a doctorate degree from Nova Southeastern University, Inc. |
| Rupert D’Souza |
Presently, Rupert D’Souza holds the position of Chief Financial & Accounting Officer of Adverum Biotechnologies, Inc.
He received an undergraduate degree from Indian Institute of Technology Bombay, a doctorate from Georgia Institute of Technology and an MBA from The University of Chicago Booth School of Business. |
| Jim Wang |
Currently, Jim Wang is Chief Regulatory Officer at Adverum Biotechnologies, Inc.
In the past Dr. Wang held the position of Manager-Regulatory CMC at Pfizer Inc., Vice President & Global Head-Regulatory Strategy at PTC Therapeutics, Inc., Executive Director-Global Regulatory Affairs at Takeda Pharmaceutical Co., Ltd. and Vice President of Spark Therapeutics, Inc.
Dr. Wang received a doctorate from the University of Illinois and an MBA from The Pennsylvania State University. |
| Jon Williams |
Jon Williams occupies the position of Vice President-Clinical Affairs at Adverum Biotechnologies, Inc.
In his past career Dr. Williams held the position of Senior Director-Clinical Affairs at Bausch Health Cos., Inc.
Dr. Williams received a doctorate from The University of California, San Francisco and an undergraduate degree from Harvey Mudd College. |
| Romuald Corbau |
Romuald Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, Inc. He previously held the same position at Freeline Therapeutics Holdings Plc from 2020 to 2021. Additionally, he served as the Chief Scientific Officer at GenEdit, Inc. Dr. Corbau is a graduate of Université des Sciences et Technologies de Lille. |
| John W. Rakow |
John W. Rakow is currently the General Counsel at Adverum Biotechnologies, Inc. He previously served as the Chief Executive Officer & General Counsel at uBiome, Inc. from 2018 to 2019. Prior to that, he was the Senior Vice President-Business & Legal Affairs at Maxar Space LLC from 2009 to 2015. He also held the position of Secretary, Senior Vice President & General Counsel at Asurion LLC in 2008. From 2016 to 2018, he worked as the Secretary, General Counsel & Senior Vice President at AppDirect, Inc. Additionally, he served as the Senior Vice President-Business & Legal Affairs at SSL Holdings, Inc. in 2014 and 2015. Mr. Rakow completed his undergraduate degree at Lewis & Clark College (Oregon) and his graduate degree at Santa Clara University. |
| Brigit Riley |
Brigit Riley holds the position of Chief Scientific Officer at Adverum Biotechnologies, Inc.
In the past she held the position of Vice President of Sangamo Therapeutics, Inc.
She received an undergraduate degree from Northwestern University and a doctorate from the University of Minnesota. |
| Linda M. Rubinstein |
Linda M. Rubinstein is currently a Partner at FLG Partners LLC since 2010 and the Chief Financial & Accounting Officer at Adverum Biotechnologies, Inc. since 2022. Previously, she served as an Independent Director at Biocept, Inc. from 2021 to 2023 and as a Director at Sensor Innovations, Inc. from 2007 to 2015. Linda also held positions at Lehman Brothers, Inc., Five Prime Therapeutics, Inc., Ingenuity Systems, Inc., Emergent Travel Health, Inc., RenovoRx, Inc., Merrill Lynch Capital Partners, Inc., Solexa, Inc., and iPierian, Inc. She was the Chief Financial Officer at Solexa, Inc. from 2005 to 2007 and the Chief Financial Officer at ArmaGen, Inc. from 2015 to 2020. Linda's education includes undergraduate and graduate degrees from the University of California, Los Angeles. |
| Clarence Patrick Machado |
Clarence Patrick Machado is the founder of Medivation, Inc. (founded in 1995) and Medivation LLC (California) (founded in 1995). He held the title of Director at both companies from 2014 to 2016. Mr. Machado's current job(s) include Chairman at Adverum Biotechnologies, Inc. (since 2017), Independent Director at Chimerix, Inc. (since 2014), Independent Director at Xenon Pharmaceuticals, Inc. (since 2020), Director at Turnstone Biologics, Inc., Independent Director at Arcus Biosciences, Inc. (since 2019), Director at Auransa, Inc., Director at Roivant Sciences, Inc., Director at ACELYRIN, Inc. (since 2021), and Member-Supervisory Board at Therachon Holding GmbH. Mr. Machado's former job(s) include Chairman at Armaron Bio Ltd., Independent Director at Inotek Pharmaceuticals Corp. (from 2016 to 2018), Director at Principia Biopharma, Inc. (from 2019 to 2020), Independent Director at Turning Point Therapeutics, Inc. (from 2019 to 2022), Independent Director at Roivant Sciences Ltd. (from 2016 to 2022), Independent Director at SCYNEXIS, Inc. (from 2015 to 2019), Independent Director at Endocyte, Inc. (in 2018), Chief Financial Officer, Director & Senior VP at Medivation Neurology LLC (from 2003 to 2004), Director at Sio Gene Therapies, Inc. (from 2017 to 2018), Director at Axovant Sciences, Inc. (from 2017 to 2018), Independent Director at Montes Archimedes Acquisition Corp., Independent Director at Turnstone Biologics Corp. (from 2018 to 2024), Chief Legal Counsel at Chiron Corp., Chief Financial Officer at Orion Acquisition Corp. II, Consultant at Cytyc Corp. (in 2002), Principal at Morrison & Foerster LLP, and Chief Financial Officer & Senior Vice President at Pro-Duct Health, Inc. (from 1998 to 2001). Mr. Machado's education includes an undergraduate degree from Santa Clara University (conferred in 1986) and a graduate degree from Harvard Law School (conferred in 1989). |
| Soo J. Hong |
Soo J. Hong is an Independent Director at Adverum Biotechnologies, Inc. and Chief People Officer at Sunbit, Inc. She previously worked as Head of Sales & Marketing at Russell Reynolds Associates, Inc. and as a Principal at Booz Allen Hamilton, Inc. She also served as Chief People Officer at National Veterinary Associates, Inc. from 2019 to 2021 and as Chief Human Resources Officer at Discovery Land Co. LLC from 2017 to 2019. Ms. Hong received her undergraduate degree from Wellesley College and her MBA from The University of Chicago Booth School of Business. |
| Scott Michael Whitcup |
Scott Michael Whitcup is the founder of Whitecap Biosciences LLC and Akrivista LLC, both founded in 2015. He held the position of Chief Executive Officer at both companies. Currently, he holds multiple positions including Director at SCILEX Pharmaceuticals, Inc., Anivive Lifesciences, Inc., and California Institute of Technology. He is also a Venture Partner at Vivo Capital LLC and an Independent Director at Adverum Biotechnologies, Inc. For former positions, he served as an Independent Director at Avanir Pharmaceuticals, Inc. from 2005 to 2014, Independent Director at Questcor Pharmaceuticals, Inc. from 2012 to 2014, Independent Director at Menlo Therapeutics, Inc. from 2015 to 2020, Director at Semnur Pharmaceuticals, Inc. from 2013 to 2019, Clinical Director at National Institutes of Health, and Clinical Director at National Eye Institute from 1993 to 2000. He was also the Chief Scientific Officer & Executive VP-Research at Allergan, Inc. from 2011 to 2015. In terms of education, he received his undergraduate degree from Cornell University and his doctorate from Weill Cornell Medical College. |
| Reed Vaughn Tuckson |
Reed Vaughn Tuckson is the founder of Black Coalition Against Covid-19. He currently holds multiple positions including Chairman at Visual Telecommunications Network, Inc., Independent Director at Henry Schein, Inc., Independent Non-Executive Director at CTI BioPharma Corp., Director at Inform Genomics, Inc., Director at Howard University, Director at Patient Advocate Foundation, Inc., Director at NeuroBioPharm, Inc., Director at Alliance for Healthcare Reform, Director at Project Sunshine, Inc., Director at American Telemedicine Association, Director at The National Patient Advocate Foundation, and Managing Director at Tuckson Health Connections LLC. He is also an Independent Director at Adverum Biotechnologies, Inc., a Director at The People-Centered Research Foundation, and a Member of the National Academy of Medicine (United States). Dr. Tuckson has held former positions including Chairman at Alliance For Health Policy, Inc., Independent Director at Legacy LifePoint Health LLC, Independent Director at Neptune Wellness Solutions, Inc., Independent Director at Acasti Pharma, Inc., Director at National Institutes of Health, Director at AcademyHealth, Chief Medical Affairs Officer & Executive VP at UnitedHealth Group, Inc., Senior Vice President-Professional Standards at American Medical Association, Trustee at Minnesota Public Radio, Trustee at The Children's Health Fund, Executive Vice President & Chief-Medical Affairs at ThedaCare, Inc., Senior Vice President-Programs at March of Dimes Foundation, and President at Charles Drew University of Medicine & Science. Dr. Tuckson's education includes an undergraduate degree from Howard University and a doctorate from Georgetown University School of Medicine. |
| C. David Nicholson |
C. David Nicholson is currently the Vice Chairman at Transcelerate Biopharma, Inc., the Chairman at Exscientia AI Ltd., the Non-Executive Chairman at Wild Bioscience Ltd., the Director at Science Exchange, Inc., the Lead Independent Director at Actinium Pharmaceuticals, Inc., the Independent Director at Adverum Biotechnologies, Inc., the Director at Tarus Therapeutics, Inc., and the Director at Volastra Therapeutics, Inc. He is also an Operational Partner at Gilde Healthcare. In his former positions, Dr. Nicholson served as the Non-Executive Chairman at Exscientia Plc, a Director at Actinium Pharmaceuticals, Inc., a Director at Cactus Ventures, Inc., a Senior Vice President at Forest Laboratories, Inc., the Vice President-Licensing & Knowledge Management at Merck & Co., Inc., the SVP-Global Project Management & Drug Safety at Schering-Plough Corp., the Chief Technology Officer & Executive VP at Bayer CropScience AG, and the Executive Vice President-Research & Development at Organon International, Inc. and Organon Biosciences, Inc. He was also the Executive VP, Chief Research & Development Officer at Allergan Ltd. (Ireland) and the CTO, Head-Research & Development at Bayer Crop Science Solutions LLC. Dr. Nicholson obtained his undergraduate degree from The University of Manchester in 1975 and his doctorate degree from The University of Wales in 1980. |
| Dawn A. Svoronos |
Dawn A. Svoronos is currently serving as the Chairman at Theratechnologies, Inc., Lead Independent Director at Xenon Pharmaceuticals, Inc., Independent Director at Adverum Biotechnologies, Inc., Director at AgNovos Healthcare LLC, Director at West Island Palliative Care Residence, Director at ACELYRIN, Inc., and Director at Teresa Dellar Palliative Care Residence. Previously, she held positions such as Chairman at The Centre for Drug Research & Development, Independent Director at PTC Therapeutics, Inc., Director at IGM Financial, Inc., Director at Endocyte, Inc., Independent Director at Medivation LLC (California), Director at AERIC, Inc., Independent Director at Global Blood Therapeutics, Inc., President at Merck Canada, Inc., President-Europe & Canada Region at Merck & Co., Inc., and Principal at Analgesics Solutions LLC and Osteoporosis Canada. She obtained her undergraduate degree from Carleton University. |
| Rabia Gurses Ozden |
Rabia Gurses Ozden is an Independent Director at Adverum Biotechnologies, Inc. and the Chief Medical Officer at Ocular Therapeutix, Inc. She previously served as the Executive Medical Director-Ophthalmology at Quark Pharmaceuticals, Inc. from 2011 to 2014. She also held the position of Vice President & Head-Clinical Ophthalmology at GSK Plc. From 2015 to 2018, she worked as the Vice President-Clinical Research & Development at Beacon Therapeutics (USA), Inc. Additionally, she was an Assistant Professor at New York Medical College. In 2019, she briefly served as the Chief Medical Officer at Nightstar Therapeutics Ltd. and later became the Chief Development Officer at Akouos, Inc. from 2019 to 2021. Dr. Ozden obtained her doctorate degree from Hacettepe University. |
| James Paul Scopa |
James Paul Scopa is currently serving as a Director at Astute Medical, Inc., Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., DICE Molecules SV, Inc., and Neuron23, Inc. In the past, he held positions as a Director at TriVascular, Inc., Conatus Pharmaceuticals, Inc., Peplin, Inc., Kalidex Pharmaceuticals, Inc., MPM BioImpact, Inc., Nevro Corp., Trivascular Technologies, Inc., Trivascular2, Inc., Solasia Pharma KK, iPierian, Inc., True North Therapeutics, Inc., Semma Therapeutics, Inc., DICE Therapeutics, Inc., Blade Therapeutics, Inc., and Cash Reserve Fund, Inc. He also worked as a Principal at Thomas Weisel Partners LLC, Alex. Brown & Sons, Inc., and Deutsche Bank Corp. Mr. Scopa obtained an MBA from Harvard Business School, a graduate degree from Harvard Law School, and an undergraduate degree from Harvard College. |
| Mark L. Lupher |
Mark L. Lupher is the founder and president of VeritasRx Consulting, which is founded in 2013. He is currently an independent director at Adverum Biotechnologies, Inc. since 2019. Dr. Lupher's former positions include being a principal at Immunex Corp., ICOS Corp., and a VP-Translational Pharmacology at Sutro Biopharma, Inc. He was also the Chief Scientific Officer at Promedior, Inc. from 2010 to 2013. Dr. Lupher is a member of The Brigham & Women's Hospital, Inc. Dr. Lupher received his doctorate from Harvard University in 1998 and his undergraduate degree from the University of Washington in 1994. |
